Beta-blockers: research of the range, socio-economic availability and volume of consumption in ukraine

Authors

  • Валентин Михайлович Толочко National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002, Ukraine
  • Оксана Яківна Міщенко National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002, Ukraine
  • Вікторія Юріївна Адонкіна National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002, Ukraine

DOI:

https://doi.org/10.15587/2313-8416.2015.57212

Keywords:

arterial hypertension, β-blockers, socio-economic availability, indicator of solvency adequacy, consumption, ATC/DDD methodology

Abstract

Beta-blockers (β-blockers) are widely used as a treatment of first choice for patients with arterial hypertension (HT). The numerous clinical studies data have shown that β-blockers hypotension effect is comparable with effects of the other first line antihypertensive remedies: calcium channel blockers, diuretics, ACE inhibitors, and angiotensin II receptor antagonists. According to the modern international recommendations for hypertension treatment, the use of selective β-blockers, as safer remedies comparing to the non-selective, is the most reasonable, but economic accessibility of remedies to the consumer is an important factor of influencing their consumption.

Aim. The analysis of the range, socio-economic availability and volume of consumption of beta-blockers in pharmaceutical market of Ukraine.

Methods. Statistical and marketing methods, WHO ATC/DDD methodology. Research objects – the data about the range, price, and the number of drug packages sold within a given year of information retrieval system “Morion”.

Results. At the beginning of 2014, in pharmaceutical market of Ukraine β-blockers were presented by 16 INN as 169 mainly foreign trade names. The group of selective β-blockers was the most widely presented – 76,6% from the general range. In 2013, the number of foreign drugs decreased by 16% compared to 2009. Propranolol, atenolol, and atenolol with chlorthalidone combination (Ca.s. = 0,21; 0,22; 0,37) were the most available; esmolol was the least available remedy. β-blockers volume of consumption has increased from 9,18 DIDs (2008) TO 13,48 DIDs (2013). The consumption of selective β-blockers was higher than both non-selective, and α- and β-blockers.

Conclusion. During 2009-2013 a decreasing of the total number of different groups of β-blockers was observed. The majority of β-blockers are high available for the average citizen of Ukraine, which allows the choice of drugs considering its efficacy, safety and cost. Esmolol drugs are the least available; propranolol and atenolol drugs are the most available. Over the period the consumption of selective β-blockers dominated, more effective and safe compared to non-selective. The displayed dynamics of consumption is a result of implementation of clinical protocols of medical care for hypertensive patients, formulary system, which promotes distribution of the evidence-based medicine principles in Ukrainian medical practice

Author Biographies

Валентин Михайлович Толочко, National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002

Doctor of Pharmacy, professor, head of department

Department of management and economics of pharmacy Institute of pharmacy professionals qualification improvement

Оксана Яківна Міщенко, National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002

Doctor of Pharmacy, associate professor of department

Department of Pharmacoeconomics

Вікторія Юріївна Адонкіна, National University of Pharmacy 53 Pushkinskaya str., Kharkiv, Ukraine, 61002

Candidate Degree in Pharmacy, senior Lecturer

Department management and economics of pharmacy Institute of pharmacy professionals qualification improvement

References

Mancia, G., Fagard, R., Narkiewicz, K. et al. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 34 (28), 2159–2219. doi: 10.1093/eurheartj/eht151

Arterial hypertension. Updated and adapted clinical guidelines based on evidence (2012)., 129. Available at: http://www.dec.gov.ua/mtd/_ag.html

Kovalenko, V. M., Luta, M. I. (Eds.) (2011). Sercevo-sudynni zahvorjuvannja. Rekomendacii' z diagnostyky, profilaktyky ta likuvannja. Kyiv: MORION, 408.

Vasan, R. S., Larson, M. G., Leip, E. P., Kannel, W. B., Levy, D. (2001). Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. The Lancet, 358 (9294), 1682–1686. doi: 10.1016/s0140-6736(01)06710-1

Podzolkov, V. I., Tarzimanova, A. I. (2011). Mesto beta-adrenoblokatorov i diuretikov v lechenii arterial'noj gipertenzii. Lechebnoe delo, 1, 43–48.

Mishhenko, O. Ja., Adonkina, V. Ju., Chynush, I. V. (2012). Farmakoepidemiologichne doslidzhennja spozhyvannja beta-adrenoblokatoriv v Ukrai'ni. Zaporozhskyj medycynskyj zhurnal, 75 (6), 17–23.

Gromovyk, B. P., Gasjuk, G. D., Levyc'ka, O. R. (2004). Farmacevtychnyj marketyng: teoretychni ta prykladni zasady. Vinnycja: Nova Knyga, 464.

Jakovljeva, L. V., Mishhenko, O. Ja., Adonkina, V. Ju. (2015). Blokatory kal'cijevyh kanaliv: doslidzhennja asortymentu, social'no-ekonomichnoi' dostupnosti ta obsjagiv spozhyvannja v Ukrai'ni. Social'na farmacija v ohoroni zdorov’ja, 1 (1), 18–23.

Mnushko, Z. M., Timanjuk, I. V. (2007). Systema zabezpechennja dostupnosti likars'kyh zasobiv. Visnyk farmacii', 1 (49), 52–57.

Morozov, A. M., Jakovljeva, L. V., Stepanenko, A. V. et. al. (2013). Vyvchennja spozhyvannja likars'kyh zasobiv za anatomo-terapevtychno-himichnoju klasyfikacijeju ta vstanovlenymy dobovymy dozamy (ATS/DDD – metodologija). Kharkiv: Styl'-Yzdat, 34.

ATC/DDD Index 2016. Available at: http://www.whocc.no/atc_ddd_index/

Helfand, M., Peterson, K., Christensen, V. (2009). Drug Class Review: Beta Adrenergic Blockers. Drug Effectiveness Review Project, 616. Available at: http://www.ncbi.nlm.nih.gov/books/NBK47172/pdf/TOC.pdf

Published

2015-12-29

Issue

Section

Pharmaceutical Sciences